GlassScriptPhysician profile
Scott J Kramer
NPI 1154648186
$3,508.77
in general payments reported to CMS, 2019-2025
27 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $580 · 2021: $165 · 2022: $229 · 2023: $491 · 2024: $347 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Education: $29.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.12 |
| Education | $29.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $802.91 | 2019-2025 | |
| Pfizer INC. | $567.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.82 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.73 | 2019-2024 | Eohilia |
| Janssen Biotech, INC. | $211.68 | 2019-2023 | Simponi, Stelara, Remicade |
| Ferring Pharmaceuticals INC. | $189.06 | 2019-2020 | |
| Allergan, INC. | $128.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $125.01 | 2023 | |
| Gilead Sciences, INC. | $94.87 | 2019-2023 | |
| Celgene Corporation | $91.61 | 2021-2022 | |
| Ardelyx, INC. | $87.73 | 2025 | Ibsrela |
| Romark Laboratories, Lc | $86.03 | 2019 | |
| Merck Sharp & Dohme LLC | $72.61 | 2019-2023 | Dificid |
| Ucb, INC. | $40.11 | 2019 | |
| Endo Pharmaceuticals INC. | $38.89 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $34.62 | 2023 | |
| Qol Medical, LLC | $29.40 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $28.50 | 2020 | |
| Echosens North America, INC. | $25.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.22 | 2024 | Voquezna |
| Amgen INC. | $18.33 | 2023 | Amjevita, Avsola |
| Shire North American Group INC | $18.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2019 | |
| Redhill Biopharma INC. | $10.99 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $8.68 | 2024 | Blueboost |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.